PolyPid Ltd. (NASDAQ:PYPD) Receives $12.25 Average Target Price from Analysts

PolyPid Ltd. (NASDAQ:PYPD) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $12.25.

Several analysts recently commented on PYPD shares. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of PolyPid in a research report on Wednesday, February 11th. Citigroup reissued a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a report on Saturday, March 14th.

Institutional Trading of PolyPid

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its position in PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares during the period. HighTower Advisors LLC acquired a new position in shares of PolyPid in the fourth quarter valued at approximately $44,000. Jane Street Group LLC purchased a new stake in shares of PolyPid during the fourth quarter worth approximately $66,000. Lumbard & Kellner LLC purchased a new stake in shares of PolyPid during the second quarter worth approximately $135,000. Finally, XTX Topco Ltd lifted its holdings in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the period. 26.47% of the stock is owned by hedge funds and other institutional investors.

PolyPid Trading Down 0.2%

Shares of NASDAQ PYPD opened at $4.15 on Thursday. The stock has a market cap of $79.19 million, a P/E ratio of -1.84 and a beta of 1.49. PolyPid has a twelve month low of $2.30 and a twelve month high of $5.12. The stock has a 50 day moving average of $4.42 and a two-hundred day moving average of $3.98.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). As a group, research analysts predict that PolyPid will post -1.79 earnings per share for the current year.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.